Ivabradine in the complex therapy of coronary heart disease and coronary heart disease complications

Cover Page

Cite item

Full Text

Abstract

Studies undertaken in recent years have shown the interaction between the frequency of heart beat and human longevity. Ivabradine is the representative of a novel class of drugs that exclusively reduce heart rate - sinus node If channel inhibitors. Ivabradine treatment significantly enhances the possibility of pharmacological management of patients with stable angina pectoris. The studies on the assessment of efficacy of ivabradine in patients with acute coronary syndrome are continuing.

About the authors

S. V Shalaev

Tyumen State Medical University; Regional Clinical Hospital №1

д-р мед. наук, проф., зав. каф. кардиологии с курсом скорой мед. помощи ГБОУ ВПО ТюмГМУ, рук. Центра сердца и сосудов ГБУЗ ТО ОКБ №1 625023, Russian Federation, Tyumen, ul. Odesskaia, d. 54

O. V Abaturova

Tyumen State Medical University

Email: obv60kafedra2016@yandex.ru
д-р мед. наук, проф. каф. кардиологии с курсом скорой мед. помощи ГБОУ ВПО ТюмГМУ 625023, Russian Federation, Tyumen, ul. Odesskaia, d. 54

L. V Kremneva

Scientific-Practical Medical Center

д-р мед. наук, вед. науч. сотр. ГАУЗ ТО НПМЦ 625000, Russian Federation, Tyumen, 4-i km Chervishevskogo trakta, d. 7, korp. 1

References

  1. Медико - демографические показатели Российской Федерации - 2006 год. Статистические материалы. М., 2007.
  2. Hasenfuss G, Holubarsch C, Herman H.P et al. Influence of the force - frequency relationship on haemodynamics and left ventricular function in patients with nonfailing hearts and in patients with dilated cardiomyopathy. Eur Heart J 1994; 15: 164-70.
  3. Green S.J, Vaduganathan M, Wilcox J.E et al. The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm. Heart Failure 2013; 6: 488-96.
  4. Лугай М.И., Лысенко А.Ф. Анализ медикаментозной терапии ишемической болезни сердца в Украине: результаты исследования PULSAR. Украинский кардиол. журн. 2010; 3: 36-43.
  5. Heidlan U.E, Strauer B.E. Left ventricular muscle mass and elevated heart rate are associated with coronary plague disruption. Circulation 2001; 104: 1477-82.
  6. Berton G.S, Cordiano R, Palmieri R et al. Heart rate during myocardial infarction: relationship with one - year global mortality in man and women. Can J Cardiol 2002; 18: 495-502.
  7. Fox K, Ford I, Steg P.G et al. Ivabravin for patient with stable coronary artery disease and left - ventricular systolic dysfunction (BEAUTIFUL): a randomized, double - blind, placebo - controlled trial. Lancet 2008; 372: 807-16.
  8. Habal М.V, Lin P.P, Austin P.C et al. Association of heart rate at hospital discharge with mortality and hospitalization on patients with heart failure. Circ Heart Failure 2013; p. 1-24.
  9. Pepine C.J, Handberg-Thurmond E, Marks R.G et al. Rationale and design of the International verapamil SR/Trandolapril Stidy (INVEST): an internet - based randomized trial in coronary artery disease patients with hypertension. JACC 1998; 1 (32): 1228-37.
  10. Bangalore S. Steg G, Deedwania P et al. B-bloker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012; 308(13): 1340-9.
  11. Lechart P, Hulot J.S, Escolano S et al. Heart rate cardiac rhytm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001; 103: 1428-33.
  12. Gullestad L, Wikstrand J, Deedwania P et al. MERIT-HF Study Group. What resting heart rate should one aim for when treating patients with heart failure with a beta - blocker? Experiences from the Metoprolol Controlled Release. Extended Release Randomized Intervention Trial in Cronic Heart Failure (MERIT-HF). J Am Coll Cardiol 2005; 45: 252-9.
  13. Hartmann F, Katus H.A. Beta blockers in heart failure therapy with special reference tj the COPERNICUS Study. Herz 2002; 27: 30-4.
  14. Wood S. Right drugs, inadequate dose: do AMI performance measures need dosing data? http// www.medscape.com/viewarticle/809807
  15. Фомин И.В. Частота сердечных сокращений при ИБС и ХСН - это банальный фактор или показатель прогноза. Человек и лекарство. Казахстан, 2012; 1 (32): 75-80.
  16. Mc Alister F.A. Meta - analysis: beta - blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009; 150: 784-94.
  17. Cerbai E, De Paoli P, Sartiani L et al. Tratment with irbesartan counteracts the functional remodeling of ventricular myovytes from hypertensive rats. J Cardiovasc Pharmacol 2003; 41: 804-12.
  18. Bucchi A, Baruscotti M, Di Francesco D. Current - dependend block of rabbit sinoatrial node If channel by ivabradin. J Gen Physiol 2002; 120: 1-13.
  19. Camm A.J, Lau C.P. Electrophysiological effects of a single intravenous administration of ivabradin (S16257) in adult patient with normal electrophysiology. Drug R D 2003; 4: 83-9.
  20. Vilaine J.P, Bidouard J.P, Lesage L et al. Anti - ischemic effects of ivabradin, a selective heart - rate reducing agent, in exercise - induced myocardial ischemia in pigs. J Cardioveasc Pharmacol 2003; 42: 688-96.
  21. Couvreur N, Tissier R, Pons S et al. Chronic heart rate reduction with ivabradine improves systolic function of the reperfused heart through a dual mechanism involving a direct mechanical effect and a long - term increase in FKBP12/12.6 expression. Eur Heart J 2010; 31: 1529-37.
  22. Zhang R.L, Christensen L.P, Tomanek R.J. Chronic heart rate reduction facilitates cardiomyocyte survival after myocardial infarction. Anat Rec (Hoboken) 2010; 293: 839-48.
  23. Морозова Т.Е., Дурнецова О.С., Вартанова О.А. и др. Рациональный выбор дифференцированной антиангинальной (антиишемической) терапии при стабильной ишемической болезни сердца. Лечащий врач. 2015; 7: 7-11.
  24. Ковалев С.А., Белов В.Н., Белова Е.А. Эффективность коррекции коронарной и сердечной недостаточности ивабрадином у больных ишемической болезнью сердца с низкой сократительной функцией левого желудочка, нуждающихся в хирургической реваскуляризации миокарда. Вестн. новых мед. технологий. 2014; 1.
  25. Пархоменко А.Н., Лутай Я.М., Иркин О.И. и др. Эффективность и безопасность раннего применения ингибитора If - каналов ивабрадина у больных с острым Q-инфарктом миокарда с синусовой тахикардией на фоне терапии блокаторами - адренорецепторов. Украiнський медичний часопис. 2012; 1: 103-10.
  26. Амосова Е.Н., Руденко Ю.В., Яо Сюй и др. Сравнительная оценка влияния комбинации ивабрадина с метопрололом и монотерапии метопрололом на продольную систолическую и диастолическую функцию левого желудочка и плазменный уровень NT-proANP у больных с острым инфарктом миокарда передней локализации. Сердце i судини. 2012; 4: 52-62.

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies